文献速递类风湿关节炎

在韩国类风湿关节炎患者中比较Janus激酶抑制剂与生物改善病情抗风湿药的现实世界有效性研究

Real-world comparative effectiveness study of Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs in Korean patients with rheumatoid arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2025-04-14

这项在韩国17个中心开展的前瞻性、多中心、观察性研究纳入506例甲氨蝶呤应答不足的类风湿关节炎患者,JAKi组与bDMARD组各253例。24周时JAKi组48.2%达到低疾病活动度,bDMARD组为42.7%;两组缓解率分别为28.9%和27.3%。48周时总体不良事件暴露调整事件率组间无显著差异,JAKi有效性及安全性与bDMARD相当。

要点

  • 24周低疾病活动度:JAKi组48.2% vs bDMARD组42.7%,缓解率28.9% vs 27.3%。
  • bDMARD组中60.1%使用TNFi(n=152),39.9%使用非TNFi(n=101)。
  • 48周总体不良事件暴露调整事件率组间无显著差异。

核心结论

  • 在符合靶向治疗条件的韩国类风湿关节炎患者中,JAKi显示出与bDMARD相当的有效性和安全性。

研究设计与样本

  • 前瞻性、多中心、观察性研究,在韩国17个中心开展。
  • 纳入甲氨蝶呤应答不足的类风湿关节炎患者,开始JAKi或bDMARD治疗,共506例,每组253例。
  • 主要终点为24周时基于DAS28-ESR评估达到低疾病活动度的患者比例。

主要发现

  • 24周时JAKi组48.2%达到低疾病活动度,bDMARD组为42.7%。
  • 24周缓解率JAKi组为28.9%,bDMARD组为27.3%。
  • 48周时总体不良事件的暴露调整事件率组间无显著差异。
  • bDMARD组中60.1%使用TNFi(n=152),39.9%使用非TNFi(n=101)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the real-world effectiveness and safety of Janus kinase inhibitors (JAKis) compared to biologic disease-modifying antirheumatic drugs (bDMARDs) in Korean patients with rheumatoid arthritis (RA) who have not previously been treated with either JAKis or bDMARDs. METHODS: This prospective, multicenter, observational study was conducted at 17 centres in the Republic of Korea. Patients with an inadequate response to methotrexate were enrolled and started treatment with either JAKis or bDMARDs. The primary endpoint was the proportion of patients achieving low disease activity (LDA) at 24 weeks, measured by the disease activity score (DAS) 28-erythrocyte sedimentation rate (ESR). Secondary endpoints included the remission rate at 24 weeks, and LDA and remission rates at 48 weeks. Safety was assessed by the exposure-adjusted event rate (EAER) of adverse events (AEs), adjusted for length of the follow-up period and presented per 100 person-years. RESULTS: A total of 506 patients were enrolled, with 253 patients in each group. Among bDMARD users, 60.1 % received tumour necrosis factor inhibitors (TNFis; n = 152) and 39.9 % received non-TNFis (n = 101). At 24 weeks, 48.2 % of the JAKi group achieved LDA, as did 42.7 % of the bDMARD group. Remission rates at 24 weeks were 28.9 % for the JAKi group and 27.3 % for the bDMARD group. At 48 weeks, there were no significant intergroup differences in the EAER of overall AEs. CONCLUSIONS: In this observational real-world study of Korean patients with RA who were eligible for targeted therapy, JAKis demonstrated comparable effectiveness and safety to bDMARDs.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Cho SK, Choi SR, Kim HW, et al. Real-world comparative effectiveness study of Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs in Korean patients with rheumatoid arthritis. Semin Arthritis Rheum. 2025. PMID: 40245585. doi:10.1016/j.semarthrit.2025.152720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。